Kestra expects $137M FY2027 revenue while targeting 70%+ gross margins in the next few years
View original at seekingalpha.comKestra expects $137M FY2027 revenue while targeting 70%+ gross margins in the next few years Earnings Call Insights: Kestra Medical Technologies (KMTS) Q4 fiscal 2026 MANAGEMENT VIEW * "We concluded fiscal 2026 with another strong quarter" and "Revenue was $28.6 million" alongside "over 6,300 prescriptions written for…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Higher revenue per fit is expected to be driven by a higher mix of in-network patients and continued revenue cycle management improvements, with in-network mix expected to remain in the low-to-mid 80s.
60% confidenceAs of Q3, Kestra was tracking towards its goal of about 130 sales territories.
60% confidenceFiscal 2026 full-year revenue came in at $95 million.
60% confidenceThere are a lot of variables in Q3 that make management nervous every year regarding seasonality.
60% confidenceThere is not something specific right in front of the company regarding the M&A tranche of the new financing.
60% confidenceKestra expects FY2027 revenue of $137 million, an increase of 44% compared to fiscal year 2026.
60% confidenceGAAP net loss was $38.8 million and adjusted EBITDA loss was $26.7 million.
60% confidenceInvestors should start to see good operating leverage in 2027 and 2028; Kestra will continue to invest in 2027, but maybe not at the same pace as 2026.
60% confidenceGross margin increased to 54.8% in the fourth quarter versus 44.3% in the prior year period, with steady, consistent increases expected going forward.
60% confidenceThere is a 6-month ramp period for new sales reps, and growth should accelerate from the first half to the second half of FY2027.
60% confidenceKestra didn't need more cash from the new term loan; the goal was a lower cost of capital plus flexibility for Biobeat-type tuck-in deals.
60% confidenceKestra had a strong financial performance across the board in fiscal 2026.
60% confidenceThe KPIs are all tracking in the right direction, giving confidence in guiding to 44% growth; Kestra is starting the fiscal year with 130 sales territories.
60% confidenceKestra ended fiscal 2026 with approximately 130 active sales territories, up from about 80 at the end of fiscal 2025; new ASSURE prescribers grew 55% and ordering facilities grew 65% in fiscal 2026.
60% confidenceTotal revenue was $28.6 million, an increase of 66% compared to the prior year period.
60% confidenceKestra concluded fiscal 2026 with another strong quarter, with revenue of $28.6 million and over 6,300 prescriptions written for the ASSURE system.
60% confidenceKestra raised FY2026 revenue guidance to $93 million as of Q3.
60% confidenceGross margin of 54.8% expanded by over 10 points year-over-year and 200 basis points sequentially; Kestra remains confident it is on a path to 70%+ gross margins over the next few years.
60% confidenceKestra will add another 40 or so sales reps and does not expect this hiring to be front-loaded.
60% confidenceGAAP operating expenses were $55 million; excluding nonrecurring costs and stock-based compensation, operating expenses were $44.7 million.
60% confidenceKestra's reps are calling on electrophysiologists but spending increasing time moving from the cath lab into general cardiology and heart failure; the company has around 70% of targeted geographic coverage today and expects to reach full coverage over the next two years.
60% confidenceKestra expects to see even more share gain, driven by both market growth and share capture.
60% confidenceThe new ASSURE algorithm update received FDA approval, discussed in Q3, and is now shipping to all patients in Q4.
60% confidenceKestra finished the year at about 46% gross margin; FY2027 gross margin is expected to increase by about 700 basis points year-over-year.
60% confidenceThe WCD market grew in the low to mid-teens and is seen growing into a multibillion-dollar market.
60% confidenceKestra is paying attention to a competitor's regulatory warning letter, but understands it was not directed at the competitor's WCD division.
60% confidenceIn Q3, Kestra's policy was to only comment on full-year FY2027 guidance at the end of the Q4 call.
60% confidenceGuideline adoption is going to be a journey, and Kestra will be publishing its ACE-PAS manuscript soon.
60% confidenceKestra issued a press release about a new $200 million term loan facility with Pharmakon, with only $75 million funded at closing, a large portion used to retire the existing term loan.
60% confidenceThere is no competitive dynamic driving the guidance level; management is being a rational team with 44% growth as an initial guide.
60% confidence